BridgeMD
New treatment option for Cardiotoxicity
Official title Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy
ClinicalTrials.gov ID: NCT07528586
What this study is testing
- What it's testing
- The goal of the trial is the early detection of cardiotoxicity in patients treated with anthracycline-based chemotherapy. Current diagnostics, such as troponin T, NT-pro-BNP, electrocardiogram, and echocardiography, are not able to identify early myocardial damage.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- \- Patients with a recommendation for antineoplastic therapy including at least four administrations of an anthracycline
You likely can't join if
- Inability to provide informed consent
- Prior administration of an anthracycline
- Administration of cardiotoxic drugs within the last six months, such as:
- High-dose cyclophosphamide (\>1,000 mg/m² or \>10 mg/kg)
- HER2 inhibitors
- VEGF inhibitors
See the full eligibility criteria
- \- Patients with a recommendation for antineoplastic therapy including at least four administrations of an anthracycline
- Inability to provide informed consent
- Prior administration of an anthracycline
- Administration of cardiotoxic drugs within the last six months, such as:
- High-dose cyclophosphamide (\>1,000 mg/m² or \>10 mg/kg)
- HER2 inhibitors
- VEGF inhibitors
- BCR-ABL inhibitors
- BRAF inhibitors
- MEK inhibitors
- Immune checkpoint inhibitors (CTLA-4 inhibitors, PD-1 inhibitors, PD-L1 inhibitors)
- Planned invasive cardiac intervention during the study period
- Cardiac involvement of an underlying disease, e.g. amyloidosis
- Treatment with fewer than four administrations of anthracyclines
- Treatment with a liposomal anthracycline formulation
- Treatment in which anthracyclines are not administered in every chemotherapy cycle
- Thoracic radiation involving the heart prior to anthracycline administration
- Participation in another clinical study concurrently or within the last three months
- Renal impairment with a GFR \< 30 ml/min/1.73 m²
- Patients in the perioperative phase of liver transplantation
- Contraindications to cardiac magnetic resonance imaging, such as metallic implants (e.g. cardiac pacemaker)
- Pregnancy or breastfeeding
- Hypersensitivity or intolerance to gadolinium-based contrast agents
- Vulnerable populations (individuals unable to protect their own interests, prisoners)
The study team makes the final eligibility decision.
Where it's taking place
- Stuttgart, Germany
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Stuttgart, Germany. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.